Copyright Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.

Size: px
Start display at page:

Download "Copyright Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited."

Transcription

1 Original article 143 Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study Jean-Pierre Olié a, Edoardo Spina b, Stephen Murray c and Ruoyong Yang c We compared the efficacy of ziprasidone and amisulpride in the treatment of negative symptoms and overall psychopathology in subjects who had chronic schizophrenia with predominantly negative symptoms. This multicentre, 12-week, double-blind study randomly assigned subjects with predominantly negative-symptom schizophrenia [i.e. Positive and Negative Syndrome Scale (PANSS) Negative Subscale score Z 6 points greater than Positive Subscale score] to ziprasidone (40 80 mg b.i.d.; n = 60) or amisulpride ( mg b.i.d.; n = 63). The primary efficacy variable was the change from baseline in PANSS Negative Subscale score. Secondary efficacy variables included change in scores for PANSS Total, Global Assessment of Functioning, Brief Psychiatric Rating Scale derived from PANSS Total and Core, Clinical Global Impression (CGI) Severity and CGI Improvement. For the change in PANSS Negative Subscale score, a ratio to assess the equivalence of the treatment groups was calculated from the least squares mean changes from baseline, with equivalence claimed if the lower limit of the 95% confidence interval of the ratio exceeded Mean daily dose, adjusted for differential numbers of subjects and differential days between visits, was mg for ziprasidone and mg for amisulpride. Mean PANSS Negative Subscale scores improved over the 12-week treatment period for intent-to-treat subjects, evaluable subjects (subjects with Z 4 weeks of double-blind treatment and no protocol deviations) and completers in both treatment groups. Ziprasidone demonstrated efficacy comparable to amulsipride in improving negative symptoms and global psychopathology. The groups demonstrated comparable improvements in secondary efficacy variables. Both agents were generally well tolerated, with comparably low incidences of movement disorders. In subjects with negative symptom prominent schizophrenia, ziprasidone in mean daily doses of 118 mg was equivalent to amisulpride in mean daily doses of 148 mg in ameliorating negative symptoms and comparable in improving overall psychopathology and global illness severity. Int Clin Psychopharmacol 21: c 2006 Lippincott Williams & Wilkins. International Clinical Psychopharmacology 2006, 21: Keywords: amisulpride, double-blind study, efficacy, negative symptoms, PANSS, schizophrenia, ziprasidone a Department of Mental Health and Therapy, Sainte-Anne Hospital, Paris, France, b Department of Clinical and Experimental Medicine and Pharmacology, Section of Pharmacology, University of Messina, Centers of Mental Health, Messina, Italy and c Pfizer Inc., New York, New York, USA. Correspondence and requests for reprints to Jean-Pierre Olié, Saint Anne Hospital, Department of Mental Health, SHU Catchment Area, 141r Cabanis, Paris, France. Tel: ; fax: ; olie@chsa.broca.inserm.fr Received 6 August 2005 Accepted 8 September 2005 Introduction Historically, the positive symptoms of schizophrenia, such as delusions, paranoia, hallucinations, conceptual disorder, and disorganized speech, have been the primary focus of antipsychotic therapy. However, negative symptoms, which include diminished social drive and emotional range, alogia, anhedonia and avolition, are increasingly viewed as critical targets for treatment (Moller et al., 1994) because their severity may predict functional and social outcomes (Ho et al., 1998). Conventional antipsychotic drugs, such as chlorpromazine and haloperidol, control positive symptoms but are less effective against negative symptoms. Moreover, these agents are commonly associated with extrapyramidal symptoms (EPS) (i.e. akathisia, dystonia, parkinsonism, and tardive dyskinesia), which may contribute to secondary or induced negative symptoms. Patients treated with conventional antipsychotics may also experience sedation and cognitive impairment. Atypical antipsychotic drugs are less likely than conventional agents to induce EPS, and appear to possess superior efficacy with regard to negative symptoms. As a consequence, they are increasingly being used as first-line treatment in schizophrenia. However, distinct tolerability issues have emerged. Some atypicals have been associated with weight gain, with olanzapine and clozapine exhibiting the greatest liability (Allison et al., 1999). Olanzapine has also been associated with alterations in the lipid profile (Osser et al., 1999; Meyer, 2001) and with disturbances in glucose metabolism, including new onset diabetes (Biswasl et al., 2001; Gianfrancesco et al., 2002; Koro et al., 2002) c 2006 Lippincott Williams & Wilkins

2 144 International Clinical Psychopharmacology 2006, Vol 21 No 3 Ziprasidone, a benzisothiazolylpiperazine, is an atypical antipsychotic that has demonstrated efficacy in multiple symptom domains in schizophrenia (Gunesekara et al., 2002). In short-term, placebo-controlled clinical trials, ziprasidone improved the positive, negative and affective symptoms of schizophrenia, with improvement observed within 1 week of treatment initiation (Keck et al., 1998; Daniel et al., 1999) and, in a 1-year trial, reduced the risk of relapse (Arató et al., 2002). Ziprasidone has shown efficacy comparable to that of haloperidol in the treatment of positive symptoms and a higher rate of negative-symptom response (Hirsch et al., 2002). Shortterm and long-term studies have demonstrated efficacy comparable to that of olanzapine (Simpson et al., 2002, 2004) and risperidone (Addington et al., 2004). Ziprasidone possesses a unique tolerability profile. Both the incidence of extrapyramidal side-effects and scores on movement disorder rating scales were lower than those for haloperidol in stable schizophrenic outpatients (Hirsch et al., 2002). In both short-term (Simpson et al., 2002) and longterm treatment (Simpson et al., 2002), ziprasidone was associated with significantly less weight gain than olanzapine, with favourable effects on lipid profiles and neutral effects on glucose metabolism. In a comparison with risperidone, ziprasidone had a lower movement disorder burden score, less weight gain and a lower incidence of prolactin elevation (Addington et al., 2004). Amisulpride is an atypical antipsychotic of the benzamide class that has shown efficacy in subjects with acute psychoses or predominantly negative-symptom schizophrenia (Curran and Perry, 2001; Leucht et al., 2002). Although unavailable in the USA, amisulpride is widely used in Europe, where comparative studies involving antidepressants have established its efficacy in depressive disorders (Lecrubier et al., 1997; Cassano and Jori, 2002; Muller et al., 2002). Other comparative studies have shown it to be as effective overall in schizophrenia as olanzapine (Martin et al., 2002) but superior to haloperidol (Carriere et al., 2000) and risperidone (Peuskens et al., 1999) with respect to negative symptoms. The primary objective of our study was to compare the efficacy of ziprasidone and amisulpride in the treatment of negative symptoms in schizophrenic subjects with predominantly negative symptomatology. We also compared the efficacy of ziprasidone and amisulpride in the treatment of general psychopathology and global illness severity, and evaluated the safety and tolerability of the two agents. Methods Study design and subjects This randomized, double-blind, parallel-group, flexibledose phase III study enrolled outpatients from 26 centres in Western Europe. Subjects included men and women aged years with a primary DSM-III-R diagnosis of chronic schizophrenia and an indication for maintenance therapy with antipsychotic medication. All patients provided their informed consent. Women either were not of child-bearing potential or were practicing contraception. Individual baseline scores on the Negative Subscale of the Positive and Negative Syndrome Scale (PANSS) had to exceed the PANSS Positive Subscale by Z 6 for inclusion in the study. Exclusion criteria included acute exacerbation of schizophrenia or psychosis 12 weeks before screening, a history of psychosurgery, or any severe medical illness. Treatment protocol Subjects underwent a minimum 3-day run-in period for screening procedures, including both psychiatric and medical evaluations. Subsequently, those who fulfilled the PANSS Negative Subscale criteria at baseline evaluation were randomized in a 1 : 1 ratio to receive ziprasidone (40, 60, or 80 mg b.i.d.) or amisulpride (50 or 100 mg b.i.d. or 50 mg a.m. and 100 mg p.m.). Doses were administered in three capsules after feeding and approximately 12 h apart. Subjects randomly assigned to ziprasidone were started on 20 mg b.i.d.; after 2 days, the dosage was increased to 40 mg b.i.d. At the discretion of the investigator, the dosage could be increased to 60 mg b.i.d. from week 2 onwards or to 80 mg b.i.d. from week 3 onwards. The starting dosage for amisulpride was 50 mg b.i.d. This could be increased to 150 mg per day from week 2 onwards and to 100 mg b.i.d. from week 3 onwards, according to clinical response. The minimum interval between dosage titration steps was 1 week. Permitted concomitant medications were lorazepam for agitation and temazapam for insomnia. Anticholinergics and propranolol were gradually withdrawn (25% dosage reduction per week) but were reinstated, if needed, at the discretion of the investigator. Evaluation of efficacy The primary efficacy variable was change from baseline in the PANSS Negative Subscale score. A relative efficacy ratio for change from baseline was used to measure the difference between amisulpride and ziprasidone in change from baseline. This method was chosen rather than absolute difference from baseline because the treatment effect of amisulpride compared to placebo on the PANSS Negative Subscale was not known. Previous placebo-controlled studies (Danion et al., 1999; Curran and Perry, 2001) with amisulpride have used the Scale for Assessment of Negative Disorders, rather than PANSS, to assess the effect of amisulpride on negative symptoms. Secondary efficacy variables were changes from baseline in the PANSS Total score, the Clinical Global Impression Severity (CGI S) and Improvement (CGI I)

3 Ziprasidone and amisulpride for negative symptoms of schizophrenia Olié et al. 145 scores, the Brief Psychiatric Rating Scale derived from PANSS (BPRSd) Total and Core scores, and the Global Assessment of Functioning (GAF) score. PANSS and CGI S were assessed at screening and then again with CGI I at baseline and weeks 4, 8 and 12 (or early termination). BPRSd Total and Core were assessed at baseline and weeks 4, 8 and 12 (or early discontinuation). GAF was assessed at baseline and week 12 (or early termination). A responder was defined as having at least a 20% decrease in PANSS Negative Subscale score at the last observation relative to baseline. A CGI responder was defined as having an observed score of 1 2 on the CGI I scale at last observation. Responder rates for each criterion were calculated for the two treatment groups. Responder rates based on 30%, 40% or 50% decrease in PANSS Negative scores were also calculated. Safety and tolerability evaluation Abnormal movements and EPS were assessed by the Simpson Angus Rating Scale, the Barnes Akathisia Scale and the Abnormal Involuntary Movement Scale (AIMS). The Barnes Akathisia Scale included one objective, two subjective and one global assessment of akathisia symptoms. The AIMS evaluation included seven items assessing tardive dyskinesia. Tests were performed at baseline and weeks 6 and 12 (or early discontinuation). The Movement Disorder Burden Score (MDBS) (Brook et al., 2005) was used to quantify overall discomfort from movement disorder adverse events occurring during the study or within 6 days of treatment cessation. All observed or volunteered adverse events were recorded regardless of suspected causal relation to the study drugs. Treatment-emergent adverse events were defined as those that were not present at baseline or those that were present at baseline but increased in severity following study drug treatment. Electrocardiogram (ECG) changes and abnormal laboratory test results that gave rise to a change of study drug dosage were recorded. Body weight measurements and ECGs were obtained at screening and week 12. Clinical laboratory tests, including blood cell counts, blood biochemistry and urinalysis, were performed at baseline and weeks 4 and 12. Analysis groups The safety population included all randomized subjects with at least one dose of study medication. The intent-to-treat (ITT) population included all randomized subjects who had a baseline and at least one post-baseline efficacy evaluation, regardless of whether protocol inclusion/exclusion criteria were met. The evaluable subjects population comprised randomized subjects who had Z 4 weeks of double-blind treatment and no major protocol deviations or violations. The Completers population comprised randomized subjects who completed the 12-week study period. Statistical analysis Efficacy analyses were performed for the ITT population, evaluable subjects, and completers. The primary inference on the comparison of treatment effects was based on the evaluable subjects population. Analyses of safety were based on the safety population. P < 0.05 (two-sided) was considered statistically significant. Statistical tests and estimates of treatment effects were based on least squares means derived from an analysis of covariance model, with baseline value as the covariate and fixedeffect terms for treatment, country, and centre nested within country. P-values and confidence intervals (CI) for differences in responder rates between the two treatment groups were obtained using normal approximation to the binomial with continuity correction. A ratio to assess the equivalence of the treatment groups was calculated from the least squares mean changes from baseline. Equivalence of the two groups was claimed if the lower limit of the 95% CI based on Fieller s Theorem of the ratio exceeded The 0.60 ratio guarantees that the difference between ziprasidone and amisulpride will be smaller than the difference between amisulpride and placebo. The differences between amisulpride and placebo in other clinical trials (Curran and Perry, 2001) have been approximately 50 55%. The selection of a 0.60 ratio also complies with the ICH guideline on equivalence margin. Although many equivalence studies use a 90% CI, a 95% CI was chosen for this study because it is considered a more stringent level (i.e. more difficult to claim equivalence). Abnormal movement scores were summarized as the percentage of subjects with a postbaseline change. Results Subject characteristics Of the 143 subjects screened, 123 were randomized and received at least 1 dose of study medication (Fig. 1). All were white, with a mean age of 39 years (Table 1) and a primary diagnosis of schizophrenia. The mean number of previous hospitalizations was greater for the amisulpride group (7.3 ± 9.8) than for the ziprasidone group (4.3 ± 7.5), whereas the mean duration of most recent hospitalization was greater for subjects treated with ziprasidone (4.0 ± 12.4 months) than for those treated with amisulpride (1.6 ± 2.7 months). Neither difference was statistically significant. In the 3 months before study entry, use of anticholinergic drugs for parkinsonism was slightly higher in the ziprasidone group (53%) than in the amisulpride group (49%). During the study, 35% of ziprasidone-treated

4 146 International Clinical Psychopharmacology 2006, Vol 21 No 3 Fig. 1 Subjects discontinued (n = 18) Ziprasidone group (n =60) Ziprasidone completers (n = 42) Subjects screened for entry (n = 143) Subjects randomized (n = 123) Amisulpride group (n = 63) Amisulpride completers (n =50) Subjects discontinued (n = 13) Disposition of subjects. Table 1 Baseline subject characteristics Ziprasidone Amisulpride Male Female Total Male Female Total No. of subjects randomized Age range (year) Mean age (year) Mean weight (kg) PANSS Negative Subscale score Subject groups (n) Safety ITT Evaluable Completers ITT, Intent-to-treat population. subjects and 21% of the amisulpride-treated subjects required anticholinergic therapy. Treatment Dosing Starting dosages (ziprasidone, 40 mg b.i.d., titrated from 20 mg b.i.d. for 2 days; amisulpride, 50 mg b.i.d.) were increased in two steps to a maximum of 80 mg b.i.d. for ziprasidone and 100 mg b.i.d. for amisulpride. The mean daily dose, adjusted for differential numbers of subjects and differential days between visits, was mg for ziprasidone and mg for amisulpride. The median duration of treatment (84 days) and the number of subjects receiving > 28 days of study drug (amisulpride group: 57/63, 90.5%; ziprasidone group: 50/60, 83.3%) were comparable for the two treatment groups. Discontinuations Thirty-one subjects were discontinued from the study. Twelve subjects (20%) in the ziprasidone group and four

5 Ziprasidone and amisulpride for negative symptoms of schizophrenia Olié et al. 147 Table 2 Changes in primary efficacy variable (baseline to last visit, all populations) Variable/population Treatment group LS (adjusted) mean change (95% CL) a Difference between groups (95% CL) b, P-value Ratio of adjusted mean change Lower limit of 95% CI for ratio PANSS Negative Intent-to-treat Ziprasidone (n =59) 6.1 ( 7.8, 4.3) 0.81 ( 1,47, 3.10), P = Amisulpride (n = 63) 6.9 ( 8.5, 5.3) Evaluable Ziprasidone (n = 50) 6.9 ( 8.6, 5.2) 1.16 ( 1.09, 3.41), P = Amisulpride (n = 53) 8.1 ( 9.7, 6.5) Completers Ziprasidone (n = 42) 9.1 ( 10.5, 7.7) 0.81 ( 2.66, 1.03), P = Amisulpride (n = 50) 8.3 ( 9.5, 7.0) a All within-group changes P < 0.001, univariate t-test. Confidence interval (CL) based on least squares (LS) (adjusted) mean change as fit by an analysis of covariance model with (fixed) effects for treatment, country and centre (nested within country), and baseline covariate. b Amisulpride Ziprasidone. CI, Confidence interval. Table 3 Changes in secondary efficacy variables (baseline to last visit, all populations) Variable/population Treatment group n LS (adjusted) mean change Difference between groups (95% CL) a (95% CL), P-value Ratio of adjusted mean change Lower limit of 95% CI for ratio PANSS Total Intent-to-treat Ziprasidone ( 16.9, 6.9) 2.78 ( 3.72, 9.27), P = Amisulpride ( 19.3, 10.0) Evaluable Ziprasidone ( 19.0, 9.2) 2.53 ( 3.80, 8.86), P = Amisulpride ( 21.2, 12.1) Completers Ziprasidone ( 24.3, 15.4) 0.50 ( 6.37, 5.38), P = Amisulpride ( 23.4, 15.4) CGI S Intent-to-treat Ziprasidone ( 0.9, 0.3) 0.11 ( 0.27, 0.48), P = Amisulpride ( 1.0, 0.5) Evaluable Ziprasidone ( 1.0, 0.4) 0.11 ( 0.27, 0.49), P = Amisulpride ( 1.1, 0.5) Completers Ziprasidone ( 1.3, 0.8) 0.15 ( 0.53, 0.23), P = Amisulpride (1.2, 0.6) BPRSd Total Intent-to-treat Ziprasidone (8.0, 2.4) 2.08 ( 1.55, 5.71), P = Amisulpride ( 9.9, 4.6) a All within-group changes P < 0.001, univariate t-test. Confidence limit (CL) based on least squares (LS) (adjusted) mean change as fit by an analysis of covariance model with (fixed) effects for treatment, country and centre (nested within country), and baseline covariate. CI, Confidence interval. (6%) in the amisulpride group were discontinued for reasons thought to be treatment related [11 (nine in the ziprasidone group, two in the amisulpride group) because of insufficient clinical response and five (three and two, respectively)] because of treatment-emergent adverse events). Other reasons for study discontinuation included adverse events not considered treatment related (n =2) and withdrawal of consent (n = 9). Efficacy assessments PANSS Negative Subscale PANSS Negative Subscale score, the primary efficacy variable, improved for both treatment groups over the 12-week study, with all three populations in each treatment group demonstrating significant improvement from baseline to endpoint (P < 0.001) (Table 2). There were no statistically significant differences between treatments in any of the populations. Both treatments demonstrated equivalent effects (defined as the lower limit of the CI of the ratio exceeding 0.60) on the PANSS Negative Subscale in the ITT population (ratio 0.88, lower limit of CI 0.60), the evaluable subjects population (ratio 0.86, lower limit of CI 0.62) and the completers population (ratio 1.10, lower limit of CI 0.89). Secondary efficacy variables Subjects in all three populations in both treatment groups improved from baseline to endpoint in the secondary efficacy variables of PANSS Total, CGI S, BPRSd Total and Core and GAF scores (P < 0.05) (Table 3). Changes in secondary efficacy variables did not differ significantly between treatment groups in any of the populations. As with the primary efficacy variable, equivalence between treatment groups for secondary efficacy variables was defined as the lower limit of the CI of the ratio exceeding Equivalence between treatments was demonstrated in the completers population for PANSS Total (ratio 1.03, lower limit of CI 0.75), CGI S (ratio 1.17, lower limit of CI 0.78), BPRSd Total (ratio 0.95, lower limit of CI 0.66) and GAF (ratio 1.31, lower limit of CI 0.84) (Table 3). Clinical response Clinical response for the various efficacy measures was defined as at least a 20% decrease in score from baseline to last visit. For the PANSS Negative Subscale score, the primary efficacy variable, response rates in the ITT population were 56% in the ziprasidone group and 62% in the amisulpride group [95% confidence limit (CL) between-group difference in percentage responders was

6 148 International Clinical Psychopharmacology 2006, Vol 21 No 3 Table 4 Clinical response rates in intent-to-treat and evaluable subjects populations Decrease in PANSS Negative Subscale score, n (%) [95% CL] a CGI Improvement 1 or 2 at last observation 20% 30% 40% 50% Intent-to-treat subjects Ziprasidone (n = 59) 33 (55.9) [21.8, 13.1] 25 (42.4) [19.7, 15.6] 15 (25.4) [12.0, 18.6] 5 (8.5) [13.5, 8.4] 24 (40.7) Amisulpride (n =63) 39 (61.9) [21.8, 13.1] 29 (46.0) [19.7, 15.6] 15 (23.8) [12.0, 18.6] 8 (12.7) [13.5, 8.4] 29 (46.0) Evaluable subjects Ziprasidone (n = 50) 31 (62.0) [27.7, 8.4] 22 (44.0) [26.2, 12.4] 13 (26.0) [17.6, 16.8] 5 (10.0) [13.7, 11.1] 22 (44.0) Amisulpride (n =53) 39 (73.6) [27.7, 8.4] 28 (52.8) [26.2, 12.4] 15 (28.3) [17.6, 16.8] 7 (13.2) [13.7, 11.1] 27 (50.9) a For between-group difference in percentage responders. CL, Confidence limit; PANSS, Positive and Negative Syndrome Scale; CGI, Clinical Global Impression. 21.8, 13.1]. The respective response rates were 62% and 74% in the evaluable subjects population (95% CL 27.7, 8.4) (Table 4). There were no statistically significant between-drug differences in response rates in either group. The number and proportion of responders and the difference in response rates decreased for both groups as the criterion was made more stringent (e.g. 30%, 40% and 50% decreases in PANSS Negative Subscale score from baseline to last visit). Response rates for evaluable subjects are shown in Fig. 2. Response rates based on a change in CGI I score of 1 or 2 from baseline were 41% and 46% for ziprasidone and amisulpride subjects, respectively, in the ITT population, and 44% and 51%, respectively, in the evaluable subjects population (Table 4). Tolerability and safety Movement disorders By a factor > 2, a higher percentage of subjects in both groups showed an overall decrease in abnormal movement disorder scores (Simpson Angus, Barnes Akathisia and AIMS) at last visit versus baseline than showed an increase (Table 5). Mean MDBS scores (0.14 for ziprasidone-treated subjects and 0.03 for amisulpridetreated subjects) did not differ significantly. Adverse events Of the 123 subjects in the safety population, 72 (58.5%) experienced an adverse event during the study or within 6 days of treatment cessation. Adverse events considered by the investigators to be related to study drug and leading to study discontinuation (three subjects in the ziprasidone group, two subjects in the amisulpride group) included severe behavioural disorders, anxiety, delusions, asthenia, EPS and insomnia in differing combinations. Treatment-emergent adverse events occurred in 36 (60%) ziprasidone subjects and 34 (54%) amisulpride subjects (Table 6). Adverse events most commonly affected the nervous system, the digestive system and the body as a whole. One subject in each group had a serious adverse event judged by the investigator to be related to the study drug. The ziprasidone subject had Fig. 2 Subjects meeting response criteria (%) Ziprasidone Amisulpride 20% 30% 40% 50% Responder rates for Positive and Negative Syndrome Scale Negative Subscale: evaluable subjects. worsening schizophrenia, EPS and avolition; the amisulpride subject, severe anxiety and asthenia. Events in both subjects resolved. Treatment-emergent adverse events occurring in Z 5% of the safety population are shown in Table 7. Laboratory events The most frequent clinically significant abnormality in blood chemistry was an increase ( Z 1 + ) in ketones, observed in 11.1% and 3.3% of subjects on ziprasidone and amisulpride, respectively. No other laboratory abnormalities occurred in Z 4% of subjects. Median values for haematology parameters, liver and renal function tests, electrolytes, thyroxine and thyroid-stimulating hormone did not change significantly from baseline. There were no clinically significant changes in QT c or QRS intervals with any dosage in either treatment group. No subject in either treatment group experienced a QT c interval Z 450 ms. A clinically significant weight increase ( > 7% of body weight) occurred in more amisulpride subjects (17.9%) than ziprasidone subjects (8.8%). The rate of clinically significant weight decrease ( > 7% of body weight) was similar in the two groups (7.0% with ziprasidone and 5.4% with amisulpride).

7 Ziprasidone and amisulpride for negative symptoms of schizophrenia Olié et al. 149 Table 5 Abnormal movement disorder scores in intent-to-treat population Parameter Ziprasidone subjects showing (%) Amisulpride subjects showing (%) n Increase Decrease No change n Increase Decrease No change Simpson Angus Barnes Akathisia AIMS AIMS, Abnormal Involuntary Movement Scale. Table 6 Treatment-emergent adverse events Adverse events summary, safety population Ziprasidone (n = 60) Amisulpride (n = 63) No. % No. % Total Serious events Nervous system Digestive system Body as a whole Clinically significant laboratory abnormalities Discontinuations due to adverse events Table 7 Treatment-emergent adverse events occurring in Z 5% of the safety population Event Subjects (%) Ziprasidone (n = 60) Amisulpride (n = 63) Insomnia Extrapyramidal syndrome Anxiety Dizziness Akathisia Somnolence Headache Asthenia Vomiting Dry mouth Nausea Discussion In this 12-week study, both ziprasidone (in total daily doses of mg) and amisulpride (in total daily doses of mg) demonstrated significant improvement in antipsychotic symptoms from baseline in subjects with chronic schizophrenia characterized by negative-symptom predominance. Response rates for negative-symptom improvement, defined as at least a 20% decrease in PANSS Negative Subscale score, were similar for ziprasidone- and amisulpride-treated subjects. Both ziprasidone and amisulpride were well tolerated, with few subjects discontinuing treatment because of adverse events. Although ziprasidone was associated with a higher rate of EPS than amisulpride, the percentage of subjects showing an overall decrease in movement disorder scores was considerably higher in both groups than the percentage showing an increase. No subject receiving either drug had prolongation of the QT c interval above 450 ms, and there was no clinically significant mean change (increase or decrease) in weight in either treatment group over the 12-week study period. Several studies have established the efficacy of amisulpride in controlling the negative symptoms of schizophrenia (Boyer et al., 1995; Danion et al., 1999; Loo et al., 1997; Rein and Turjanski, 1997) at dosages comparable to those used here. Our study provides evidence of the efficacy of ziprasidone with respect to negative symptoms. The efficacy of ziprasidone in this regard was also demonstrated in a 28-week study of outpatients with stable schizophrenia (Hirsch et al., 2002). In that study, ziprasidone not only proved superior to haloperidol in controlling negative symptoms, but was also associated with a lower liability for EPS. In addition to acute symptom improvement, long-term symptom control is important for schizophrenic patients with a preponderance of negative symptomatology because full remission is less likely if primary negative symptoms become an enduring feature of psychosis (Carpenter et al., 1988). In a recent 1-year placebocontrolled study of hospitalized subjects with chronic, stable schizophrenia, ziprasidone was associated with a statistically significant improvement in the PANSS Negative Symptom Subscale score. Importantly, treatment with ziprasidone was also shown to significantly lower the probability of relapse compared to placebo (Arató et al., 2002). The present study was not designed to compare treatment efficacy with respect to the positive symptoms of schizophrenia, and subjects in our study did not have acute exacerbation of schizophrenia. Although amisulpride in dosages of 100 mg per day is effective in improving the negative symptoms of schizophrenia (Boyer et al., 1994; Danion et al., 1999), dosages Z 400 mg per day are considered optimal for controlling acute schizophrenia (Burns and Bale, 2001). However, the incidence of EPS with amisulpride is dose-related, increasing to 37% at mg per day (Curran and Perry, 2001). Ziprasidone has demonstrated efficacy against both acute and chronic schizophrenia in negative and positive symptom domains within the same dosage range (i.e mg per day), and has a favourable

8 150 International Clinical Psychopharmacology 2006, Vol 21 No 3 tolerability profile with respect to movement disorders at those dosages. Possible limitations of our study include an apparent disparity in subjects baseline characteristics and differences in discontinuation rates between the two treatment groups. Although subjects in the current study were generally well matched with respect to history of psychiatric illness, the mean number of previous psychiatric hospitalizations was greater in the amisulpride-treated group (trend towards significance versus ziprasidone). This might suggest that subjects randomized to amisulpride were more ill at baseline than those randomized to ziprasidone. However, given the vast number of baseline parameters that were collected and analysed, a finding of borderline significance in one baseline parameter should be not regarded as either surprising or necessarily clinically relevant. Although there was a higher rate of discontinuation due to insufficient clinical response in the ziprasidone than the amisulpride group, this was likely due to protocoldefined dosage limitations in our study. A dosage of 80 mg b.i.d. has previously been shown to improve the negative symptoms of schizophrenia (Daniel et al., 1999). However, our subjects did not achieve this dosage until day 21, which may have affected clinical response. In a pooled analysis of placebo-controlled trials, discontinuation rates for ziprasidone were lower within the first 14 days of treatment initiation in subjects who received mg b.i.d. (5.2%) than in those who received mg b.i.d. (11.5%) (Murray et al., 2003). The mean decrease from baseline in BPRS Total scores within the first 14 days of treatment initiation was greater in subjects who received 60 mg b.i.d. ( 3.14; P < 0.05 versus placebo) or 80 mg b.i.d. ( 5.62; P r 0.001) than in those who received 20 mg b.i.d. ( 1.51; P = NS) or 40 mg b.i.d. ( 0.62; P = NS) (Murray et al., 2003). Furthermore, flexible-dose trials of ziprasidone versus olanzapine or haloperidol in which ziprasidone was titrated from 80 mg/day to 160 mg/ day over several days had lower rates of discontinuation due to inadequate clinical response than a trial versus risperidone in which titration of ziprasidone occurred over 2 weeks (8.8%, 10.7%, and 14.8% in the trials versus olanzapine, haloperidol and risperidone, respectively) (Murray et al., 2003). In our study, both ziprasidone and amisulpride showed equivalence in improving negative symptoms. In three identically designed 6-week, open-label switch studies, ziprasidone was associated with significant improvement in PANSS Negative Subscale scores in subjects switched from conventional agents (P < 0.01), olanzapine (P < 0.01) and risperidone (P < ). Improvement was sustained during the continuation phase of the studies (P < 0.05 versus baseline in those switched from olanzapine, P < 0.01 in those switched from conventionals and P < in those switched from risperidone) (Schooler et al., 2003). Ziprasidone dosing in these studies was 80 mg per day for 2 days, followed by mg per day through week 6 (Weiden et al., 2003) and the continuation phase (overall median 215 days) (Schooler et al., 2003). A limitation of our own study may thus be suboptimal dosing of ziprasidone (i.e. the adjusted mean daily dose was 118 mg, which is lower than the currently recommended optimal dosage of Z 60 mg b.i.d.) (Murray et al., 2003). Similarly, the literature cites amisulpride dosages of mg per day as appropriate to significantly reduce the negative symptoms of schizophrenia (Curran and Perry, 2001). In the present study, the adjusted mean daily dose of amisulpride was mg. However, even with the limitation in ziprasidone dosing, ziprasidone-treated subjects demonstrated negativesymptom reduction comparable to that of amisulpridetreated subjects. References Addington DEN, Pantelis C, Dineen M, Benattia I, Romano SJ (2004). Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, doubleblind, multicenter trial. J Clin Psychiatry 65: Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, et al. (1999). Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156: Arató M, O Connor R, Meltzer HY (2002). A 1-year, double-blind, placebocontrolled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. Int Clin Psychopharmacol 17: Biswasl PN, Wilton LV, Pearcel GL, Freemantle S, Shakir SA (2001). The pharmacovigilance of olanzapine: results of a post-marketing surveillance study of 8858 subjects in England. J Psychopharmacol 15: Boyer P, Lecrubier Y, Puech AJ, Dewailly J, Aubin F (1995). Treatment of negative symptoms in schizophrenia with amisulpride. Br J Psychiatry 166: Brook S, Walden J, Benattia I, Siu CO, Romano SJ (2005). Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: Comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study. Psychopharmacology 178: Burns T, Bale R (2001). Clinical advantages of amisulpride in the treatment of acute schizophrenia. J Int Med Res 29: Cassano GB, Jori MC, for the AMIMAJOR Group (2002). Efficacy and safety of amisulpride 50 mg versus paroxetene 20 mg in major depression: a randomized, double-blind, parallel group study. Int Clin Psychopharmacol 17: Carpenter WT Jr, Heinrichs DW, Wagman AM (1988). Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry 145: Carriere P, Bonhomme D, Lemperiere T (2000). Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicenter, double-blind study (the Amisulpride Study Group). Eur Psychiatry 15: Curran MP, Perry CM (2001). Amisulpride: a review of its use in the management of schizophrenia. Drugs 61: Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M (1999). Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology 20: Danion JM, Rein W, Fleurot O (1999). Improvement of schizophrenic subjects with primary negative symptoms treated with amisulpride. Amisulpride Study Group. Am J Psychiatry 156: Gianfrancesco FD, Grogg AL, Mahmoud RA, Wang RH, Nasrallah HA (2002). Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. J Clin Psychiatry 63: Gunesekara NS, Spencer CM, Keating GM (2002). Ziprasidone: a review of its use in schizophrenia and schizoaffective disorder. Drugs 62:

9 Ziprasidone and amisulpride for negative symptoms of schizophrenia Olié et al. 151 Hirsch SR, Kissling W, Bauml J, Power A, O Connor R (2002). A 28-week comparison of ziprasidone and haloperidol in outsubjects with stable schizophrenia. J Clin Psychiatry 63: Ho BC, Nopoulos P, Flaum M, Arndt S, Andreasen NC (1998). Two-year outcome in first-episode schizophrenia: predictive value of symptoms for quality of life. Am J Psychiatry 155: Keck P Jr, Buffenstein A, Ferguson J, Feighner J, Jaffe W, Harrigan EP, Morrissey MR (1998). Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology (Berl) 140: Koro CE, Fedder DO, L Italien GJ, Weiss SS, Magder LS, Kreyenbuhl J, et al. (2002). Assessment of independent effect of olanzapine and risperidone on risk of diabetes among subjects with schizophrenia: population based nested case-control study. BMJ 325: Lecrubier Y, Boyer P, Turjanski S, Rein W (1997). Amisulpride versus imipramine and placebo in dysthymia and major depression. Amisulpride Study Group. J Affect Disord 43: Leucht S, Pitschel-Walz G, Engel RR, Kissling W (2002). Amisulpride, an unusual atypical antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry 159: Loo H, Poirier-Littre MF, Theron M, Rein W, Fleurot O (1997). Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia. Br J Psychiatry 170: Martin S, Ljo H, Peuskens J, Thirumalai S, Giudicelli A, Fleurot O, et al. (2002). A double-blind, randomized comparative trial of amisulpride versus olanzapine in the treatment of schizophrenia: short-term results at two months. Curr Med Res Opin 18: Meyer JM (2001). Novel antipsychotics and severe hyperlipidemia. J Clin Psychopharmacol 21: Moller HJ, van Praag HM, Aufdembrinke B, Bailey P, Barnes TR, Beck J, et al. (1994). Negative symptoms in schizophrenia: considerations for clinical trials. Working group on negative symptoms in schizophrenia. Psychopharmacology (Berl) 115: Muller MJ, Wetzel H, Benkert O (2002). Differential effects of high-dose amisulpride versus flupentixol on latent dimensions of depressive and negative symptomatology in acute schizophrenia: an evaluation using confirmatory factor analysis. Int Clin Psychopharmacol 17: Murray S, Siu C, Romano SJ (2003). Optimal dosing of oral ziprasidone: analysis of clinical trial data. Presented at the Annual Meeting of the American Psychiatric Association; May; San Francisco, California, USA. Osser DN, Najarian DM, Dufresne RL (1999). Olanzapine increases weight and serum triglyceride levels. J Clin Psychiatry 60: Peuskens J, Bech P, Moller HJ, Bale R, Fleurot O, Rein W (1999). Amisulpride versus risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpride study group. Psychiatry Res 88: Rein W, Turjanski S (1997). Clinical update on amisulpride in deficit schizophrenia. Int Clin Psychopharmacol 12 (suppl 2):S19 S27. Schooler NR, Murray S, Siu C, Romano S (2003). Ziprasidone negative symptom efficacy in long-term trials. Presented at the Annual Meeting of the American Psychiatric Association; May; San Francisco, California, USA. Simpson GM, Weiden P, Pigott T, Romano SJ, Siu CO (2002). Ziprasidone versus olanzapine in schizophrenia: 6-month continuation study. Presented at the 54th Institute on Psychiatric Services; 9 13 October; Chicago, Illinois, USA. Simpson GM, Glick ID, Weiden PJ, Romano SJ, Siu CO (2004). Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Am J Psychiatry 161: Weiden PJ, Simpson GM, Potkin SG, O Sullivan RL (2003). Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia. J Clin Psychiatry 64:

SYNOPSIS. Study Coordinator. Study centre(s)

SYNOPSIS. Study Coordinator. Study centre(s) Drug product: Seroquel Drug substance(s): Quetiapine Document No.: 1 Edition No.: 1 Study code: D1449C00005 Date: 02 January 2007 SYNOPSIS A Randomized, Parallel Group, Open Trial Examining the Safety,

More information

Summary ID#7029. Clinical Study Summary: Study F1D-MC-HGKQ

Summary ID#7029. Clinical Study Summary: Study F1D-MC-HGKQ CT Registry ID# 7029 Page 1 Summary ID#7029 Clinical Study Summary: Study F1D-MC-HGKQ Clinical Study Report: Versus Divalproex and Placebo in the Treatment of Mild to Moderate Mania Associated with Bipolar

More information

Is Aristada (Aripiprazole Lauroxil) a Safe and Effective Treatment For Schizophrenia In Adult Patients?

Is Aristada (Aripiprazole Lauroxil) a Safe and Effective Treatment For Schizophrenia In Adult Patients? Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 12-2016 Is Aristada (Aripiprazole Lauroxil)

More information

SYNOPSIS. ER OROS Paliperidone: Clinical Study Report R SCH-301

SYNOPSIS. ER OROS Paliperidone: Clinical Study Report R SCH-301 SYNOPSIS Protocol No.: R076477-SCH-301 Title of Study: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With an Open-Label Extension Evaluating Extended Release OROS Paliperidone in

More information

(+)-3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-ethyl]- 6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H-pyridol[1,2-a]pyrimidin-4- one

(+)-3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-ethyl]- 6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H-pyridol[1,2-a]pyrimidin-4- one SYNOPSIS Issue Date: 18 November 2008 Document No.: EDMS-PSDB-9006510:2.0 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Ortho-McNeil Janssen Scientific Affairs, L.L.C. Paliperidone

More information

Paliperidone: Clinical Protocol R076477SCH4012, CR Amendment INT-1

Paliperidone: Clinical Protocol R076477SCH4012, CR Amendment INT-1 Paliperidone: Clinical Protocol R076477SCH4012, CR013771 Amendment INT-1 A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of a Fixed

More information

SYNOPSIS. Risperidone-R064766: Clinical Study Report RIS-USA-232 (FOR NATIONAL AUTHORITY USE ONLY)

SYNOPSIS. Risperidone-R064766: Clinical Study Report RIS-USA-232 (FOR NATIONAL AUTHORITY USE ONLY) SYNOPSIS Protocol No.: RIS-USA-232 Title of Study: Efficacy and Safety of a Flexible Dose of Risperidone Versus Placebo in the Treatment of Psychosis of Alzheimer's Disease Principal Investigator: M.D.

More information

Clinical Advantages of Amisulpride in the Treatment of Acute Schizophrenia

Clinical Advantages of Amisulpride in the Treatment of Acute Schizophrenia The Journal of International Medical Research 2001; 29: 451 466 Clinical Advantages of Amisulpride in the Treatment of Acute Schizophrenia T BURNS 1 AND R BALE 2 1 Department of Psychiatry; 2 Department

More information

SYNOPSIS INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER (FOR NATIONAL AUTHORITY USE ONLY) Volume: Page:

SYNOPSIS INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER (FOR NATIONAL AUTHORITY USE ONLY) Volume: Page: SYNOPSIS Risperdal Risperidone (R064766) Protocol No.: RIS-USA-150 Part 1 INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER AUTHORITY USE ONLY) Title of Study: A Double-Blind, Placebo-Controlled

More information

Class Update: Oral Antipsychotics

Class Update: Oral Antipsychotics Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

SYNOPSIS (FOR NATIONAL AUTHORITY USE ONLY) INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER

SYNOPSIS (FOR NATIONAL AUTHORITY USE ONLY) INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER SYNOPSIS Protocol No.: RIS-USA-63 Psychosis in Alzheimer s disease (PAD) analysis Title of Study: A randomized, double-blind, placebo controlled study of risperidone for treatment of behavioral disturbances

More information

Symptoms of schizophrenia are usually categorized as positive

Symptoms of schizophrenia are usually categorized as positive PHARMACOLOGY NOTES Ziprasidone mesylate (Geodon for injection): the first injectable atypical antipsychotic medication VALERIE SHEEHAN, PHARMD Symptoms of schizophrenia are usually categorized as positive

More information

INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER Volume: Page:

INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER Volume: Page: SYNOPSIS Protocol No.: CR004357 Title of Study: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of 50 and 100 mg eq. of Paliperidone Palmitate in Subjects With

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium olanzapine 210mg, 300mg, 405mg powder and solvent for prolonged release suspension for injection (ZypAdhera ) No. (624/10) Eli Lilly and Company Limited 09 July 2010 The Scottish

More information

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 1 February 2012

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 1 February 2012 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 1 February 2012 XEPLION 25 mg, prolonged-release suspension for injection 1 pre-filled polycycloolefin syringe with

More information

BRL /RSD-101C0D/1/CPMS-704. Report Synopsis

BRL /RSD-101C0D/1/CPMS-704. Report Synopsis Report Synopsis Study Title: A Randomized, Multicenter, 10-Week, Double-Blind, Placebo- Controlled, Flexible-Dose Study to Evaluate the Efficacy and Safety of Paroxetine in Children and Adolescents with

More information

Role of Clozapine in Treatment-Resistant Schizophrenia

Role of Clozapine in Treatment-Resistant Schizophrenia Disease Management and Treatment Strategies Elkis H, Meltzer HY (eds): Therapy-Resistant Schizophrenia. Adv Biol Psychiatry. Basel, Karger, 2010, vol 26, pp 114 128 Role of Clozapine in Treatment-Resistant

More information

Janssen-Cilag EMEA Medical Affairs a division of Janssen Pharmaceuticals N.V.

Janssen-Cilag EMEA Medical Affairs a division of Janssen Pharmaceuticals N.V. SYNOPSIS Issue Date: Final 22 July 2009 [Document No.: EDMS-PSDB-9245102] Name of Sponsor/Company Name of Finished Product Risperdal Consta Name of Active Ingredient(s) Protocol No.: RIS-BMN-3001 Janssen-Cilag

More information

SYNOPSIS. Risperidone-R064766: Clinical Study Report RIS-INT-24 (FOR NATIONAL AUTHORITY USE ONLY)

SYNOPSIS. Risperidone-R064766: Clinical Study Report RIS-INT-24 (FOR NATIONAL AUTHORITY USE ONLY) SYNOPSIS Protocol No.: RIS-INT-24 Psychosis in Alzheimer s disease (PAD) analysis Title of Study: Risperidone in the treatment of behavioral disturbances in demented patients: an international, multicenter,

More information

Abbreviated Class Review: Long-Acting Injectable Antipsychotics

Abbreviated Class Review: Long-Acting Injectable Antipsychotics Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Abbreviated Class Review: Long-Acting Injectable Antipsychotics

Abbreviated Class Review: Long-Acting Injectable Antipsychotics Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Treatment of Schizophrenia

Treatment of Schizophrenia Treatment of Schizophrenia Conduct comprehensive assessment and use measurement-based care as found in the Principles of Practice (review pages 4-7). Most importantly assess social support system (housing,

More information

Sponsor. Novartis Pharmaceuticals Corporation Generic Drug Name. Agomelatine Therapeutic Area of Trial. Major depressive disorder Approved Indication

Sponsor. Novartis Pharmaceuticals Corporation Generic Drug Name. Agomelatine Therapeutic Area of Trial. Major depressive disorder Approved Indication Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Corporation Generic Drug Name Therapeutic Area of Trial Major depressive disorder Approved Indication Investigational drug Study

More information

Alternative Thresholds for Negative and Positive Symptoms in the CATIE Trial: Implications for Negative Symptom Clinical Trials

Alternative Thresholds for Negative and Positive Symptoms in the CATIE Trial: Implications for Negative Symptom Clinical Trials Alternative Thresholds for Negative and Positive Symptoms in the CATIE Trial: Implications for Negative Symptom Clinical Trials Eduardo Dunayevich, Chao-Yin Chen, Stephen Marder and Jonathan Rabinowitz

More information

Diagnosis and treatment of acute agitation and aggression in patients with schizophrenia and bipolar disorder: evidence for the efficacy of atypical

Diagnosis and treatment of acute agitation and aggression in patients with schizophrenia and bipolar disorder: evidence for the efficacy of atypical Diagnosis and treatment of acute agitation and aggression in patients with schizophrenia and bipolar disorder: evidence for the efficacy of atypical antipsychotics 1 Abstract Acute agitation and aggression

More information

AMISULPRIDE VERSUS RISPERIDONE IN THE TREATMENT

AMISULPRIDE VERSUS RISPERIDONE IN THE TREATMENT AMISULPRIDE VERSUS RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIC PATIENTS: A DOUBLE-BLIND PILOT STUDY IN TAIWAN Tzung J. Hwang, 1 Shin-Min Lee, 2 Hsiao-Ju Sun, 3 Hsin-Nan Lin, 1 Shih-Jen Tsai, 4 Ying-Chiao

More information

Treatment of Children and Adolescents with Schizophrenia

Treatment of Children and Adolescents with Schizophrenia Treatment of Children and Adolescents with Schizophrenia The evidence base pertaining to the pharmacotherapy of schizophrenia in children and adolescents (C&A) is tiny compared to what is available for

More information

Lurasidone: A New Antipsychotic For Schizophrenia. Objectives. Introduction. Pharmacology/Pharmacokinetics. Mechanism of Action. Mechanism of Action

Lurasidone: A New Antipsychotic For Schizophrenia. Objectives. Introduction. Pharmacology/Pharmacokinetics. Mechanism of Action. Mechanism of Action Lurasidone: A New Antipsychotic For Schizophrenia Theodore Pikoulas, PharmD PGY2 Psychiatric Pharmacy Resident Louis Stokes Cleveland VAMC Objectives Review the pharmacology and the pharmacokinetics Identify

More information

) and serotonin Type 2 (5-HT 2A

) and serotonin Type 2 (5-HT 2A Latuda (lurasidone HCl) Fact Sheet Schizophrenia FREQUENTLY ASKED QUESTIONS What type of patient with schizophrenia is appropriate for LATUDA? LATUDA is an atypical antipsychotic agent indicated for the

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Psychosis and Agitation in Dementia

Psychosis and Agitation in Dementia Psychosis and Agitation in Dementia Dilip V. Jeste, MD Estelle & Edgar Levi Chair in Aging, Director, Stein Institute for Research on Aging, Distinguished Professor of Psychiatry & Neurosciences, University

More information

BRL /RSD-101RLL/1/CPMS-716. Report Synopsis

BRL /RSD-101RLL/1/CPMS-716. Report Synopsis Report Synopsis Study Title: A Multicenter, Open-label, Six-Month Extension Study to Assess the Long-term Safety of Paroxetine in Children and Adolescents with Major Depressive Disorder (MDD) or Obsessive-Compulsive

More information

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI)

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI) PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.

More information

How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials

How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials ORIGINAL ARTICLE How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials S Leucht 1, D Arbter 1, RR Engel 2, W Kissling 1 and JM Davis 3 (2009) 14, 429 447

More information

Eight Core Principles for Treating Psychosis in Adolescents. Sanjiv Kumra MD. Off-Label Use. Psychosis/Schizophrenia in U.S. Children/Adolescents

Eight Core Principles for Treating Psychosis in Adolescents. Sanjiv Kumra MD. Off-Label Use. Psychosis/Schizophrenia in U.S. Children/Adolescents Off-Label Use Eight Core Principles for Treating Psychosis in Adolescents Sanjiv Kumra MD Some of the medications described in this presentation constitute off-label use Objectives At the conclusion of

More information

SYNOPSIS. Risperidone-R064766: Clinical Study Report RIS-AUS-5 (FOR NATIONAL AUTHORITY USE ONLY)

SYNOPSIS. Risperidone-R064766: Clinical Study Report RIS-AUS-5 (FOR NATIONAL AUTHORITY USE ONLY) SYNOPSIS Protocol No.: RIS-AUS-5 Psychosis in Alzheimer s disease (PAD) analysis Title of Study: Risperidone in the treatment of behavioral and psychological symptoms in dementia: a multicenter, double-blind,

More information

Method. NeuRA First versus second generation antipsychotics August 2016

Method. NeuRA First versus second generation antipsychotics August 2016 Introduction First generation typical are an older class of antipsychotic than second generation atypical. First generation are used primarily to treat positive symptoms including the experiences of perceptual

More information

Trial No.: RIS-USA-102 Clinical phase: III

Trial No.: RIS-USA-102 Clinical phase: III SYNOPSIS Trial identification and protocol summary Company: Johnson & Johnson Pharmaceutical Research and Development, a division of Janssen Pharmaceutica, N.V. Finished product: Risperdal Active ingredient:

More information

New Medications in Early Psychosis

New Medications in Early Psychosis New Medications in Early Psychosis Jean Starling Department of Psychological Medicine, the Children s Hospital at Westmead Department of Psychological Medicine and Department of Paediatrics and Child Health,

More information

Schizophrenia and bipolar disorders are lifelong

Schizophrenia and bipolar disorders are lifelong THE STANDARD OF CARE IN TREATING PSYCHIATRIC DISORDERS Peter J. Weiden, MD,* and David G. Daniel, MD ABSTRACT In recent years, several guidelines and algorithms have appeared to help clinicians address

More information

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall

More information

Pharmacotherapy of psychosis and schizophrenia in youth

Pharmacotherapy of psychosis and schizophrenia in youth Pharmacotherapy of psychosis and schizophrenia in youth Benedetto Vitiello Pavia, 2 December 2017 Disclosure Benedetto Vitiello, M.D. Professor of Child and Adolescent Neuropsychiatry University of Turin,

More information

Double-Blind Comparison of Olanzapine versus Clozapine in Schizophrenic Patients Clinically Eligible for Treatment with Clozapine

Double-Blind Comparison of Olanzapine versus Clozapine in Schizophrenic Patients Clinically Eligible for Treatment with Clozapine Double-Blind Comparison of Olanzapine versus Clozapine in Schizophrenic Patients Clinically Eligible for Treatment with Clozapine Gary D. Tollefson, Martin A. Birkett, Gerilyn M. Kiesler, Andrew J. Wood,

More information

Lurasidone for the treatment of schizophrenia. Lead author: Gavin Mankin Regional Drug & Therapeutics Centre (Newcastle) February 2015

Lurasidone for the treatment of schizophrenia. Lead author: Gavin Mankin Regional Drug & Therapeutics Centre (Newcastle) February 2015 Lurasidone for the treatment of schizophrenia Lead author: Gavin Mankin Regional Drug & Therapeutics Centre (Newcastle) February 2015 2015 Summary Lurasidone is a second generation (atypical) antipsychotic

More information

West Midlands DEC Reports

West Midlands DEC Reports 30 March 1998 West Midlands DEC Reports 15 Appendices Appendix 1...32 Appendix 2...37 Appendix 3...39 Appendix 4...45 Appendix 5...52 March 1998 West Midlands DEC reports 31 Appendix 1 Evidence on efficacy

More information

Recent Advances in the Antipsychotic Treatment of People with schizophrenia. Robert W. Buchanan, M.D.

Recent Advances in the Antipsychotic Treatment of People with schizophrenia. Robert W. Buchanan, M.D. Recent Advances in the Antipsychotic Treatment of People with schizophrenia Robert W. Buchanan, M.D. Antipsychotic medications are the primary class of drugs used in the pharmacological treatment of schizophrenia.

More information

Clinical Trial Results Database Page 1

Clinical Trial Results Database Page 1 Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Corporation Generic Drug Name Therapeutic Area of Trial Major Depressive Disorder (MDD) Approved Indication Treatment of major depressive

More information

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 30 November 2011

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 30 November 2011 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 30 November 2011 List of medicines concerned: SECOND-GENERATION ORAL ANTIPSYCHOTICS SOLIAN 100 mg, 200 mg, 400 mg

More information

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 18 February 2009

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 18 February 2009 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 February 2009 ABILIFY 5 mg tablets, pack of 28 (CIP: 364 069-7) ABILIFY 10 mg tablets, pack of 28 (CIP: 364 073-4)

More information

CLINICAL STUDY REPORT SYNOPSIS

CLINICAL STUDY REPORT SYNOPSIS CLINICAL STUDY REPORT SYNOPSIS Document No.: EDMS-PSDB-6511694:4.0 Name of Sponsor/Company Johnson & Johnson Pharmaceutical Research & Development Name of Finished Product Name of Active Ingredient Protocol

More information

Optima Health. Schizophrenia. Next Review Date 9/19

Optima Health. Schizophrenia. Next Review Date 9/19 Optima Health Schizophrenia Guideline History Original Approve Date 04/01 Review/Revise 3/05, 12/06, 09/08, 11/08, Dates 11/10, 7/11, 7/13, 7/15, 9/17 Next Review Date 9/19 These Guidelines are promulgated

More information

Presented at the American Psychiatric Association Annual Meeting May 20 24, 2017 San Diego, CA.

Presented at the American Psychiatric Association Annual Meeting May 20 24, 2017 San Diego, CA. Original Presentations Key Words: amines, antipsychotic agents, double-blind method, mood disorders, psychopharmacology, psychotic disorders, schizophrenia, tardive dyskinesia, valbenazine Efficacy of

More information

Version 5.1: June ZYPADHERA Olanzapine powder & solvent for prolonged release suspension for injection

Version 5.1: June ZYPADHERA Olanzapine powder & solvent for prolonged release suspension for injection ZYPADHERA Olanzapine powder & solvent for prolonged release suspension for injection Patients Treated with Depot Antipsychotics May.. Have had multiple relapses and/or recent hospitalizations Have a history

More information

Lurasidone Benefit assessment according to 35a Social Code Book V 1

Lurasidone Benefit assessment according to 35a Social Code Book V 1 IQWiG Reports Commission No. A14-42 Lurasidone Benefit assessment according to 35a Social Code Book V 1 Extract 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Lurasidon Nutzenbewertung

More information

Resubmission. Scottish Medicines Consortium

Resubmission. Scottish Medicines Consortium Scottish Medicines Consortium Resubmission aripiprazole 5mg, 10mg, 15mg, 0mg tablets; 10mg, 15mg orodispersible tablets; 1mg/mL oral solution (Abilify ) No. (498/08) Bristol-Myers Squibb Pharmaceuticals

More information

Antipsychotic Medications

Antipsychotic Medications TRAIL: Team Review of EVIDENCE REVIEW & RECOMMENDATIONS FOR LTC Behavioural and psychological symptoms of dementia (BPSD) refer to the non-cognitive symptoms of disturbed perception, thought content, mood

More information

New Medicines Committee Briefing November 2011

New Medicines Committee Briefing November 2011 New Medicines Committee Briefing November 2011 Paliperidone long-acting injection (Xeplion ) for schizophrenia Paliperidone palmitate long-acting injection (Xeplion ) is to be reviewed for use within:

More information

The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements

The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements Schizophrenia Bulletin vol. 36 no. 1 pp. 71 93, 2010 doi:10.1093/schbul/sbp116 Advance Access publication on December 2, 2009 The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations

More information

Application for the Inclusion of New Medications for the WHO Formulary

Application for the Inclusion of New Medications for the WHO Formulary 17th Expert Committee on the Selection and Use of Essential Medicines Geneva, 2009 Application for the Inclusion of New Medications for the WHO Formulary 1. Summary Statement of the Proposal for Inclusion

More information

The Efficacy and Safety of Lower Doses of Aripiprazole for the Treatment of Patients with Acute Exacerbation of Schizophrenia

The Efficacy and Safety of Lower Doses of Aripiprazole for the Treatment of Patients with Acute Exacerbation of Schizophrenia The Efficacy and Safety of Lower Doses of for the Treatment of Patients with Acute Exacerbation of Schizophrenia By Andrew J. Cutler, MD, Ronald N. Marcus, MD, Sterling A. Hardy, MS, Amy O Donnell, MD,

More information

R (paliperidone palmitate) Clinical Study Report R SCA-3004

R (paliperidone palmitate) Clinical Study Report R SCA-3004 SYNOPSIS Name of Sponsor/Company Janssen Scientific Affairs, LLC Name of Finished Product INVEGA SUSTENNA Name of Active Ingredient(s) Status: Approved Date: 10 March 2014 Prepared by: Janssen Scientific

More information

SiGMA/ MMHSCT GUIDELINES FOR ANTIPSYCHOTIC DRUG TREATMENT OF SCHIZOPHRENIA. [compatible with NICE guidance]

SiGMA/ MMHSCT GUIDELINES FOR ANTIPSYCHOTIC DRUG TREATMENT OF SCHIZOPHRENIA. [compatible with NICE guidance] SiGMA/ MMHSCT GUIDELINES FOR ANTIPSYCHOTIC DRUG TREATMENT OF SCHIZOPHRENIA [compatible with NICE guidance] Medicines Management Committee August 2002 For review August 2003 Rationale The SiGMA algorithm

More information

Is Lurasidone more safe and effective in the treatment ofschizoaffective disorder and schizophrenia than other commonanti-psychotic medications?

Is Lurasidone more safe and effective in the treatment ofschizoaffective disorder and schizophrenia than other commonanti-psychotic medications? Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2015 Is Lurasidone more safe and effective

More information

WARNING LETTER DEPARTMENT OF HEALTH & HUMAN SERVICES TRANSMITTED BY FACSIMILE

WARNING LETTER DEPARTMENT OF HEALTH & HUMAN SERVICES TRANSMITTED BY FACSIMILE DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Rockville, MD 20857 TRANSMITTED BY FACSIMILE Ajit Shetty, M.D. CEO Janssen Pharmaceutica, Inc. 1125 Trenton-Harbourton

More information

Handout for the Neuroscience Education Institute (NEI) online activity: First-Episode Schizophrenia: Setting the Stage for Successful Outcomes

Handout for the Neuroscience Education Institute (NEI) online activity: First-Episode Schizophrenia: Setting the Stage for Successful Outcomes Handout for the Neuroscience Education Institute (NEI) online activity: First-Episode Schizophrenia: Setting the Stage for Successful Outcomes Learning Objectives Initiate low-dose antipsychotic medication

More information

Minimising the Impact of Medication on Physical Health in Schizophrenia

Minimising the Impact of Medication on Physical Health in Schizophrenia Minimising the Impact of Medication on Physical Health in Schizophrenia John Donoghue Liverpool Imagination is more important than knowledge Albert Einstein LIFESTYLE Making choices TREATMENT Worse Psychopathology,

More information

SYNOPSIS. Trial No.: RIS-USA-70 Clinical phase: III. JRF, Clinical Research Report RIS-USA-70, 16 October, 1998 N Trial period: Start: 20 Nov 95

SYNOPSIS. Trial No.: RIS-USA-70 Clinical phase: III. JRF, Clinical Research Report RIS-USA-70, 16 October, 1998 N Trial period: Start: 20 Nov 95 SYNOPSIS Trial identification and protocol summary Company: Janssen Research Foundation Finished product: RISPERDAL Active ingredient: Risperidone (R064,766) Title: An open-label, long-term study of risperidone

More information

Switching antipsychotics: Basing practice on pharmacology & pharmacokinetics

Switching antipsychotics: Basing practice on pharmacology & pharmacokinetics Switching antipsychotics: Basing practice on pharmacology & pharmacokinetics John Donoghue Liverpool L imagination est plus important que le savoir Albert Einstein Switching Antipsychotics: Objectives

More information

Technology appraisal guidance Published: 26 January 2011 nice.org.uk/guidance/ta213

Technology appraisal guidance Published: 26 January 2011 nice.org.uk/guidance/ta213 Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years Technology appraisal guidance Published: 26 January 2011 nice.org.uk/guidance/ta213 NICE 2018. All rights reserved. Subject

More information

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 2 November 2011

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 2 November 2011 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 2 November 2011 SYCREST 5 mg, sublingual tablet B/60 (CIP code: 415 241-6) B/100 (CIP code: 579 353-1) SYCREST 10

More information

CLINICAL STUDY REPORT SYNOPSIS

CLINICAL STUDY REPORT SYNOPSIS CLINICAL STUDY REPORT SYNOPSIS Document No.: EDMS-PSDB-7176909:2.0 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient Protocol No.: CR002350 Johnson & Johnson Pharmaceutical Research

More information

I received help from Bosch Health Care

I received help from Bosch Health Care John Kasckow, MD, PhD VA Pittsburgh Health Care System Western Psychiatric Institute and Clinic, UPMC VA Pittsburgh Health Care System I received help from Bosch Health Care 1 Diagnoses of Interest Early

More information

Summary ID# Clinical Study Summary: Study B4Z-MC-LYBX

Summary ID# Clinical Study Summary: Study B4Z-MC-LYBX CT Registry ID#7068 Page 1 Summary ID# 7068 Clinical Study Summary: Study B4Z-MC-LYBX A Randomized, Double-Blind Comparison of Hydrochloride and Placebo in Child and Adolescent Outpatients with Attention-

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Subotnik KL, Casaus LR, Ventura J, et al. Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia:

More information

Sponsor Novartis. Generic Drug Name. NA (not existing yet) Therapeutic Area of Trial Parkinson s Disease L-dopa induced dyskinesia

Sponsor Novartis. Generic Drug Name. NA (not existing yet) Therapeutic Area of Trial Parkinson s Disease L-dopa induced dyskinesia Page 1 Sponsor Novartis Generic Drug Name NA (not existing yet) Therapeutic Area of Trial Parkinson s Disease L-dopa induced dyskinesia Approved Indication Investigational. Study Number CA2206 Title A

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Positive and Negative Symptom Response to Clozapine in Schizophrenic Patients With and Without the Deficit Syndrome

Positive and Negative Symptom Response to Clozapine in Schizophrenic Patients With and Without the Deficit Syndrome BUCHANAN, POSITIVE Am J Psychiatry AND BREIER, NEGATIVE 155:6, KIRKPATRICK, June SYMPTOM 1998 ET RESPONSE AL. Positive and Negative Symptom Response to Clozapine in Schizophrenic With and Without the Deficit

More information

Ingrezza. (valbenazine) New Product Slideshow

Ingrezza. (valbenazine) New Product Slideshow Ingrezza (valbenazine) New Product Slideshow Introduction Brand name: Ingrezza Generic name: Valbenazine Pharmacological class: Vesicular monoamine transporter 2 (VMAT2) inhibitor Strength and Formulation:

More information

Individualising antipsychotic treatment for patients with schizophrenia John Donoghue Liverpool

Individualising antipsychotic treatment for patients with schizophrenia John Donoghue Liverpool Copyright John Donoghue 2015 Individualising antipsychotic treatment for patients with schizophrenia John Donoghue Liverpool Copyright John Donoghue 2015 QUESTIONS Why do outcomes in schizophrenia remain

More information

CDEC FINAL RECOMMENDATION

CDEC FINAL RECOMMENDATION CDEC FINAL RECOMMENDATION ARIPIPRAZOLE LONG-ACTING INJECTION (Abilify Maintena Otsuka Pharmaceuticals Co. & Lundbeck Canada Inc.) Indication: Schizophrenia Recommendation: The Canadian Drug Expert Committee

More information

What s new in Mental Health?

What s new in Mental Health? What s new in Mental Health? Sheri Andrews BSc.(Pharm) MSc.(EBP) Mental Health Program SERHA (RHA B) CSHP-NB AGM 2008 May 24, 2008 Countdown to delivery: 155 days Objectives Highlight new medications available

More information

a division of Janssen Pharmaceuticals N.V.

a division of Janssen Pharmaceuticals N.V. SYNOPSIS Issue Date: Final 26 November 2008 Document No.: EDMS-PSDB-9183291 Name of Sponsor/Company Name of Finished Product Risperdal Consta Name of Active Ingredient(s) Protocol No.: RIS-SCH-3001 Janssen-Cilag

More information

SYNOPSIS. Trial identification and protocol summary

SYNOPSIS. Trial identification and protocol summary SYNOPSIS Trial identification and protocol summary Company: JANSSEN PHARMACEUTICA N.V. Finished product: Risperdal Active ingredient: Risperidone (R64766) Title: The safety and efficacy of risperidone

More information

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI)

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI) PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.

More information

9/16/2016. I would feel comfortable dispensing/prescribing varenicline to a patient with a mental health disorder. Learning Objectives

9/16/2016. I would feel comfortable dispensing/prescribing varenicline to a patient with a mental health disorder. Learning Objectives The Smoking Gun: for Smoking Cessation in Patients with Mental Health Disorders BRENDON HOGAN, PHARMD PGY2 PSYCHIATRIC PHARMACY RESIDENT CTVHCS, TEMPLE, TX 09/23/2016 I would feel comfortable dispensing/prescribing

More information

Summary ID#236 Clinical Study Summary: Study B1Y-MC-HCCJ

Summary ID#236 Clinical Study Summary: Study B1Y-MC-HCCJ CT Registry ID#236 Page 1 Summary ID#236 Clinical Study Summary: Study B1Y-MC-HCCJ Title of Study: Fluoxetine: Fluoxetine versus Placebo in Adolescent Depressed Patients Investigator(s): This single-center

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable: Studies listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Appendix D: Included Studies adverse effects review

Appendix D: Included Studies adverse effects review DELIRIUM APPENDICES (Draft for Consultation) Appendix D: Included Studies adverse effects review Table D1: Studies directly comparing two antipsychotic agents in delirium Author Study design Setting Age

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Clozapine as Add-On Medication in the Maintenance Treatment of Bipolar and Schizoaffective Disorders

Clozapine as Add-On Medication in the Maintenance Treatment of Bipolar and Schizoaffective Disorders Neuropsychobiology 2002;45(suppl 1):37 42 Clozapine as Add-On Medication in the Maintenance Treatment of Bipolar and Schizoaffective Disorders A Case Series B. Hummel S. Dittmann A. Forsthoff N. Matzner

More information

SYNOPSIS. Clinical Study Report CN138002: Addendum 1. Individual Study Table Referring to the Dossier

SYNOPSIS. Clinical Study Report CN138002: Addendum 1. Individual Study Table Referring to the Dossier Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Abilify Name of Active Ingredient: aripiprazole Individual Study Table Referring to the Dossier (For National Authority Use Only)

More information

Method. NeuRA Paliperidone August 2016

Method. NeuRA Paliperidone August 2016 Introduction Second generation antipsychotics (sometimes referred to as atypical antipsychotics) are a newer class of antipsychotic medication than first generation typical antipsychotics. Second generation

More information

A systematic review of atypical antipsychotic drugs in schizophrenia. Atypical antipsychotic drugs in schizophrenia

A systematic review of atypical antipsychotic drugs in schizophrenia. Atypical antipsychotic drugs in schizophrenia A systematic review of atypical antipsychotic drugs in schizophrenia Atypical antipsychotic drugs in schizophrenia A-M Bagnall 1 * S Gilbody 3 L Jones 1 L Davies 4 L Ginnelly 2 D Torgerson 2 R Lewis 1

More information

Objectives. Epidemiology. Diagnosis 3/27/2013. Identify positive and negative symptoms used for diagnosis of schizophrenia

Objectives. Epidemiology. Diagnosis 3/27/2013. Identify positive and negative symptoms used for diagnosis of schizophrenia Objectives Identify positive and negative symptoms used for diagnosis of schizophrenia Mohamed Sallout, Pharm D. Pharmacist Resident St. Luke s Magic Valley Regional Medical Center List medications used

More information

BRL /RSD-101C0F/1/CPMS-716. Report Synopsis

BRL /RSD-101C0F/1/CPMS-716. Report Synopsis Report Synopsis Study Title: A Multicenter, Open-label, Six-Month Extension Study to Assess the Long-Term Safety of Paroxetine in Children and Adolescents with Major Depressive Disorder (MDD) or Obsessive-Compulsive

More information

2. SYNOPSIS Name of Sponsor/Company:

2. SYNOPSIS Name of Sponsor/Company: in patients with refractory partial seizures 14 Jun 2007 2. SYNOPSIS TITLE OF STUDY: Efficacy and safety of BIA 2-093 as adjunctive therapy for refractory partial seizures in a double-blind, randomized,

More information

Suboptimal Response in Psychotic & Mood Disorders: Causes, Consequences, and Management Strategies

Suboptimal Response in Psychotic & Mood Disorders: Causes, Consequences, and Management Strategies Suboptimal Response in Psychotic & Mood Disorders: Causes, Consequences, and Management Strategies Henry A. Nasrallah, MD Sydney W. Souers Professor and Chair, Department of Psychiatry, Saint Louis University,

More information

Antipsychotics: The Essentials. Module 5: A Primer on Selected Antipsychotics

Antipsychotics: The Essentials. Module 5: A Primer on Selected Antipsychotics Antipsychotics: The Essentials Module 5: A Primer on Selected Antipsychotics Slide 1 Recently approved antipsychotics Iloperidone (Fanapt) - 2009 Asenapine (Saphris, Sycrest) - 2009 Lurasidone (Latuda)

More information

journal of medicine The new england Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia abstract

journal of medicine The new england Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia abstract The new england journal of medicine established in 1812 september 22, 2005 vol. 353 no. 12 Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia Jeffrey A. Lieberman, M.D., T. Scott

More information